Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01HL142118 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | NIH |
Not provided
Not provided
Not provided
Not provided
People living with HIV (PLWH) often have poor sleep, which may put them at a higher risk for many chronic diseases, including cardiovascular disease. One of the mechanisms by which this may occur is via chronic inflammation and endothelial dysfunction. Adenosine plays an important role in sleep homeostasis, with levels increasing in the CSF in response to sleep deprivation and falling with sleep. Peripherally, adenosine, via its signaling pathway, plays an important role in immunoregulation by suppressing the inflammatory response. PLWH, even on antiretroviral therapy, have suppressed peripheral adenosine levels which are predictive of adverse cardiovascular outcomes. The hypothesis underlying this study is that acute sleep deprivation in PLWH does not result in a compensatory increase in extracellular adenosine and its signaling peripherally, and this failure to appropriately compensate, leads to an increase in systemic inflammation and endothelial dysfunction.
People living with HIV infection (PLWH) are known to be at higher risk of cardiovascular disease and also have a higher prevalence of poor sleep than people who do not have HIV infection. Understanding the underlying mechanisms for the elevated risk of cardiovascular disease in PLWH is important to developing novel strategies to mitigate this risk. Poor sleep has been postulated to mediate some of the elevated cardiovascular risk in PLWH given the high prevalence of poor sleep in PLWH and the epidemiologic association of poor sleep with adverse cardiovascular outcomes among people who do not have HIV infection. However, the mechanisms by which PLWH may be more sensitive to sleep loss from a cardiovascular standpoint are unclear. One potential explanation for any elevated sensitivity would be via alterations in the adenosine signaling pathway.
Changes in extracellular adenosine levels in the brain and central nervous system play an important homeostatic role in sleep-wake regulation. Sleep deprivation results in a rise in extracellular adenosine levels while sleep itself leads to a rapid decline in levels. Peripheral adenosine signaling is a central feature of immunoregulation, primarily through its effects on inflammatory cytokine expression and lymphocyte adenosine receptor expression. PLWH tend to have a suppressed level of peripheral adenosine signaling and this level of suppression predicts risk of cardiovascular disease. The purpose of this study is to explore the impact of acute sleep deprivation among PLWH on measures of inflammation and endothelial function and to assess the extent to which any changes may be explained by alterations in peripheral adenosine signaling.
The study will enroll 40 PLWH, age 18-75, who have been on ART for greater than 48 weeks. Screening with questionnaires, actigraphy and polysomnography will eliminate individuals with underlying chronic sleep abnormalities. A prior night of polysomnography in the sleep lab will also habituate subjects to sleeping while monitored in the sleep lab.
Participants will arrive in the sleep laboratory in the evening and be allowed to sleep for 8 hours timed to their usual sleep patterns. On waking, participants will provide a urine sample that will be assayed for adenosine and adenosine metabolites. Blood will be drawn to measure markers of inflammation as well as markers of activation of the peripheral adenosine signaling system. Endothelial function will be assessed using flow mediated dilation.
Participants will be kept awake for the subsequent 24 hours including the 8 hour normal sleep period. On the second morning, subjects will again provide urine and blood samples for the same bioassays described above and then undergo repeat assessment of endothelial function.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sleep deprivation | Experimental | All subjects will be provided an 8 hour opportunity for sleep (Night 1) followed by outcome assessment the next morning (Day 1). They will then be kept awake the subsequent 24 hours including Night 2, followed by outcome assessment the following morning (Day 2). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sleep deprivation | Behavioral | Eight hour opportunity for sleep followed by 24 hours of sleep deprivation. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Soluble CD14 | Plasma concentration of soluble CD14 | Baseline sleep replete state and after 24 hours of sleep deprivation |
| Soluble CD163 | Plasma concentration of soluble CD163 | Baseline sleep replete state and after 24 hours of sleep deprivation |
| IL6 | Plasma concentration of interleukin-6 | Baseline sleep replete state and after 24 hours of sleep deprivation |
| Measure | Description | Time Frame |
|---|---|---|
| Flow Mediated Brachial Artery Dilation | Percent change was calculated by measuring the brachial artery diameter at baseline and then the percent dilation from this baseline after release of occlusion at each time point. | Baseline sleep replete state and after 24 hours of sleep deprivation |
| Monocyte Expression of IL6 |
| Measure | Description | Time Frame |
|---|---|---|
| Plasma Adenosine | Plasma adenosine concentration | Baseline sleep replete state and after 24 hours of sleep deprivation |
| Plasma Inosine | Plasma inosine concentration |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sanjay R Patel, MD | University of Pittsburgh | Principal Investigator |
| Bernard J Macatangay, MD | University of Pittsburgh | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15260 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Sleep Repletion Followed by Sleep Deprivation | An 8 hour opportunity for sleep followed by outcome assessment the next morning and then 24 hour sleep deprivation followed by repeat outcome assessment. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Baseline (Sleep Repletion) Followed by Sleep Deprivation | An 8 hour opportunity for sleep followed by outcome assessment the next morning and then 24 hour sleep deprivation followed by repeat outcome assessment. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Soluble CD14 | Plasma concentration of soluble CD14 | Posted | Mean | Standard Deviation | ng/mL | Baseline sleep replete state and after 24 hours of sleep deprivation |
|
|
24 hours
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Baseline (Sleep Repletion) Followed by Sleep Deprivation | An 8 hour opportunity for sleep followed by outcome assessment the next morning and then 24 hour sleep deprivation followed by repeat outcome assessment. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Petechiae | Skin and subcutaneous tissue disorders | Non-systematic Assessment | Petechiae on arm from blood pressure cuff inflation for brachial artery reactivity testing. |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Sanjay R. Patel MD, MS | University of Pittsburgh | 412-383-0607 | patelsr2@upmc.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Jul 13, 2023 | Jul 14, 2023 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D012892 | Sleep Deprivation |
| D007249 | Inflammation |
| ID | Term |
|---|---|
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |
| D009422 | Nervous System Diseases |
| D009461 | Neurologic Manifestations |
Not provided
Not provided
All participants will undergo one night of normal sleep (Night 1) followed by a subsequent night (Night 2) of sleep deprivation. Outcomes will be assessed the morning (Day 1 and Day 2) after each condition.
Not provided
Not provided
Technicians processing biospecimens will be blinded to whether samples were collected on Day 1 or Day 2. Similarly, the assessor of brachial artery reactivity measurements will be blinded to whether ultrasound images were collected on Day 1 or Day 2.
Not provided
Percentage of circulating CD14+ peripheral blood mononuclear cells expressing interleukin-6 |
| Baseline sleep replete state and after 24 hours of sleep deprivation |
| Monocyte Expression of TNF-alpha | Percentage of circulating CD14+ peripheral blood mononuclear cells expressing tumor necrosis factor-alpha | Baseline sleep replete state and after 24 hours of sleep deprivation |
| CD4+ T-cell Expression of HLA-DR and CD38 | Percentage of CD3+ CD4+ T-lymphocytes co-expressing HLA-DR and CD38 | Baseline sleep replete state and after 24 hours of sleep deprivation |
| CD8+ T-cell Expression of HLA-DR and CD38 | Percentage of CD3+ CD8+ T-lymphocytes co-expressing HLA-DR and CD38 | Baseline sleep replete state and after 24 hours of sleep deprivation |
| Baseline sleep replete state and after 24 hours of sleep deprivation |
| Urine 3'5'-cAMP | Urine 3'5'-cyclic adenosine monophosphate concentration normalized to creatinine | Baseline sleep replete state and after 24 hours of sleep deprivation |
| CD4+ T-cell Expression of CD39 and/or CD73 | Percentage of CD3+ CD4+ T-lymphocytes expressing CD39 and/or CD73 | Baseline sleep replete state and after 24 hours of sleep deprivation |
| CD8+ T-cell Expression of CD39 and/or CD73 | Percentage of CD3+ CD8+ T-lymphocytes expressing CD39 and/or CD73 | Baseline sleep replete state and after 24 hours of sleep deprivation |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
|
| Primary | Soluble CD163 | Plasma concentration of soluble CD163 | All 20 participants who completed the protocol and whose blood sample met quality control for the assay performed. | Posted | Mean | Standard Deviation | ng/mL | Baseline sleep replete state and after 24 hours of sleep deprivation |
|
|
|
| Primary | IL6 | Plasma concentration of interleukin-6 | All 20 participants who completed the protocol and whose blood sample met quality control for the assay performed. | Posted | Mean | Standard Deviation | pg/mL | Baseline sleep replete state and after 24 hours of sleep deprivation |
|
|
|
| Secondary | Flow Mediated Brachial Artery Dilation | Percent change was calculated by measuring the brachial artery diameter at baseline and then the percent dilation from this baseline after release of occlusion at each time point. | Posted | Mean | Standard Deviation | % change | Baseline sleep replete state and after 24 hours of sleep deprivation |
|
|
|
| Secondary | Monocyte Expression of IL6 | Percentage of circulating CD14+ peripheral blood mononuclear cells expressing interleukin-6 | Posted | Mean | Standard Deviation | % cells | Baseline sleep replete state and after 24 hours of sleep deprivation |
|
|
|
| Secondary | Monocyte Expression of TNF-alpha | Percentage of circulating CD14+ peripheral blood mononuclear cells expressing tumor necrosis factor-alpha | Posted | Mean | Standard Deviation | % cells | Baseline sleep replete state and after 24 hours of sleep deprivation |
|
|
|
| Secondary | CD4+ T-cell Expression of HLA-DR and CD38 | Percentage of CD3+ CD4+ T-lymphocytes co-expressing HLA-DR and CD38 | Posted | Mean | Standard Deviation | % cells | Baseline sleep replete state and after 24 hours of sleep deprivation |
|
|
|
| Secondary | CD8+ T-cell Expression of HLA-DR and CD38 | Percentage of CD3+ CD8+ T-lymphocytes co-expressing HLA-DR and CD38 | Posted | Mean | Standard Deviation | % cells | Baseline sleep replete state and after 24 hours of sleep deprivation |
|
|
|
| Other Pre-specified | Plasma Adenosine | Plasma adenosine concentration | Not Posted | Baseline sleep replete state and after 24 hours of sleep deprivation | Participants |
| Other Pre-specified | Plasma Inosine | Plasma inosine concentration | Not Posted | Baseline sleep replete state and after 24 hours of sleep deprivation | Participants |
| Other Pre-specified | Urine 3'5'-cAMP | Urine 3'5'-cyclic adenosine monophosphate concentration normalized to creatinine | Not Posted | Baseline sleep replete state and after 24 hours of sleep deprivation | Participants |
| Other Pre-specified | CD4+ T-cell Expression of CD39 and/or CD73 | Percentage of CD3+ CD4+ T-lymphocytes expressing CD39 and/or CD73 | Not Posted | Baseline sleep replete state and after 24 hours of sleep deprivation | Participants |
| Other Pre-specified | CD8+ T-cell Expression of CD39 and/or CD73 | Percentage of CD3+ CD8+ T-lymphocytes expressing CD39 and/or CD73 | Not Posted | Baseline sleep replete state and after 24 hours of sleep deprivation | Participants |
| 0 |
| 20 |
| 0 |
| 20 |
| 1 |
| 20 |
|
Not provided
Not provided
| D012816 |
| Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001523 | Mental Disorders |
| D010335 | Pathologic Processes |
|
|